Selected features of nonendocrine pancreatic cancer

Experimental Biology and Medicine

Volumn 226, Issue 6, 2001, Pages 521-537

  Anderson, Ken M ^a   Harris, Jules E ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

Topics in non endocrine pancreatic cancer

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; COMPLEMENTARY DNA;

APOPTOSIS; CANCER CELL; CELL PROLIFERATION; GENE EXPRESSION; GENE REPRESSION; MALIGNANT TRANSFORMATION; PANCREAS CANCER; PANCREAS CELL; SHORT SURVEY; SUICIDE GENE;

EID: 0034994676     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020122600604     Document Type: Short Survey

References (190)

1. Apoptosis in cancer therapy: Crossing the threshold
2. Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line
3. 5-Lipoxygenase inhibitors reduce PC-3 proliferation and initiate non-necrotic cell death
4. Cell and molecular biology of pancreatic carcinoma
5. Biliopancreatic malignancy: From gene to cure
6. Genetics of pancreatic cancer: From genes to families
7. Familial pancreatic cancers
8. The molecular genetics of pancreatic cancer
9. Molelcular prognostic markers in pancreatic cancer
10. The link between exocrine pancreatic cancer and the endocrine pancreas
11. Allelotype of pancreatic adenocarcinomas using xenograft enrichment
12. Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genome hybridization
13. Consistent chromosome abnormalities in adenocarcinoma of the pancreas
14. Loss of chromosonme 18q is an early event in pancreatic ductal tumorigenesis
15. Gene expression in pancreatic adenocarcinoma
16. Germline and somatic mutations of the STK11/LKB 1 Peutz-Jeghers gene in pancreatic and biliary cancers
17. Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1 and BRCA2 mutations
18. Germline BRCA2 6174de1T mutations in Ashkenazhi Jewish pancreatic cancer patients
19. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations
20. Serial analysis of gene expression
21. Identifying markers for pancreatic cancer by gene exression analysis
22. A pancreatic-specific expression profile
23. Fivelipoxygenase inhibitors reduce Panc-1 survival: The mode of cell death and synergism of MK 886 with gamma linolenic acid
24. Altered oncogene, tumor suppressor and cell-cycle gene expression in Panc-1 cells cultured with the pleiotrophic 5-lipoxygenase inhibitor. MK 886, assessed with a gene chip
25. MK 886 functions as a radiomimetic agent: Genomic responses related to oxidative stress, the cell cycle, proliferation and programmed cell death in Panc-1 cells
26. Widespread countervailing genomic responses induced by chemotherapy or radiation as a cause of therapeutic failure
27. Most human carcinomas of the exocrine pancreas contain mutant c-k-ras genes
28. Activation of Raf-1 in human pancreatic adenocarcinoma
29. K-ras-2 topographic genotyping of pancreatic adenocarcinoma
30. Identification of genes showing differential expression in antisense K-ras transduced pancreatic cancer cells with suppressed tumorigenicity
31. Overexpression of HER2/neu oncogene in human pancreatic carcinoma
32. Molecular genetics of pancreatic cancer
33. Differentiation stagespecific inhibition of the Raf-MEK-ERK pathway by Akt
34. Phosphorylation and regulation of Raf by Akt (protein kinase B)
35. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene
36. Frequent somatic mutations and homozygous deletions of the p16 (MST1) gene in pancreatic adenocarcinoma
37. Abrogation of the Rb/p16 tumor suppressive pathway in virtually all pancreatic adenocarcinoma
38. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic cancer
39. P53 mutations in pancreatic carcinoma and evidence of common involvement of homopolymer tracts in DNA microdeletions
40. Clinical significance of serum p53 antigen in patients with pancreatic cancer
41. DPC4, a candidate tumor supressor gene at human chromosome 18q21.1
42. Tumor suppressor gene SMAD4/DPC4, its downstream target genes, and regulation of cell cycle
43. Loss of expression of DPC4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression
44. Tumor-suppressive pathways in pancreatic carcinoma
45. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas
46. Abnormalities of the RBI and DCC tumor suppressor gene: Uncommon in human pancreatic carcinoma
47. C-met expression in pancreatic cancer and effects of hepatocyte growth factor on pancreatic cancer cell growth
48. The FHIT gene is expressed in pancreatic ductal cells and is altered in pancreatic cancers
49. Alterations in pancreatic, biliary and breast carcinomas support MKK4 as a generally targeted tumor suppressor gene
50. p16 and k-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma
51. kipi expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma
52. waf/cip-1 and p53 expression in pancreatic adenocarcinoma
53. Overexpression of cyclin D1 in human pancreatic crcinomas is associated with poor prognosis
54. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes
55. S6K pathway in human pancreatic cancer cells
56. Src stimulated insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells
57. Hypermethylation of multiple genes in pancreatic adenocarcinoma
58. Nuclear DNA content and pathology in radically treated pancreatic carcinoma: The prognostic significance of DNA ploidy, histology and nuclear grade
59. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology
60. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer
61. Association of BRCA 1 with the hRAD50 hMrell-p95 complex and the DNA damage response
62. DNA adducts, oxidative DNA damage and genetic polymorphisms in pancreatic cancer
63. Expression of growtharrest and DNA damage-inducible (GADD) 45 protein in resectable invasive ductal carcinoma (IDC) of the pancreas
64. Growth factors and cytokines in pancreatic carcinogenesis
65. Growth factors and growth factor receptors in pancreatic cancer
66. Regression of human pancreatic carcinoma and inhibition of metastases by blockade of EGF-R signal transduction is enhanced in combination with gemcitabine
67. Cytokines and the biology of pancreatic cancer
68. Overexpression of the TGF-β-regulated zinc finger encoding gene, TIEG induces apoptosis in pancreatic epithelial cells
69. Epithelial-stromal interactions
70. Gastrointestinal peptides and receptors in pancreatic cancer
71. The cell biology of pancreatic cancer: An overview
72. Identification and characterization of IL-13 and IL-4 receptor complex in pancreatic carcinoma cells
73. Inhibition of epidermal growth factor-induced interleukin-1β-converting enzyme expression reduces proliferation in the pancreatic carcinoma cell line AsPC-1
74. Insulin-like growth factor 1 overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles
75. Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer
76. Overexpression of acidic and basic fibroblast growth factors in pancreatic cancer correlate with advanced tumor state
77. Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma
78. WAF/CIP1
79. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis
80. 12-Lipoxygenase activity stimulated pancreatic cancer cell proliferation through activation of the ERK MAP kinase pathway
81. Cell death: Programmed, apotosis, necrosis or other?
82. Immunohistochemical analysis of Bcl-2, Bax, and Mcl-1 expression in pancreatic cancer
83. Human pancreatic adenocarcinoma express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis
84. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by BCL-2 content
85. BCL-XL protects human pancreatic carcinoma cells against trail-induced apoptosis
86. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells
87. NTBN, a free radical spins trap, induces programmed cell death in human pancreatic cancer (PANC-1) cells
88. BCL-2 is expressed in U937 but absent in PC-3 and Panc-1 cells
89. MGI 114 induces a multiple caspase activation cascade in human pancreatic cancer
90. Proteasome inhibitor PS-341 effective as an anti-angiogenetic agent in the treatment of human pancreatic carcinoma via the inhibition of NF-kB and subsequent inhibition of vascular endothelial growth factor production
91. An essential role for NH-kB in preventing TNF-induced cell death
92. TNF and cancer therapy- induced apoptosis: Potentiation by inhibition of NF-kB
93. Suppression of TNF-α-induced apoptosis by NF-kB
94. A possible mechanism for escape from FAS-mediated apoptosis in pancreatic invasive ductal carxcinoma (ICD)
95. Cross-talk between IGF-1R and EGFR signaling in maintaining growth fraction independence and resistance to apoptosis in the pancreatic cancer cell line MIA PACA-2
96. Inhibition of phosphati-dylinositol 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells
97. BCL-2 family members as mediators of RAS-induced transformation
98. Salicylates inhibit NF-kB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cncer cells
99. Apoptosis and drug response
100. Role of oncogenes in resistence and killing by cancer therapeutic agents
101. Does maximizing programmed cell death necessarily yield an optimum clinical advantage?
102. Apoptosis versus necrosis: Which should be the aim of cancer therapy?
103. The effect of exogenous lipids on cancer and cancer chemotherapy
104. Medical roles of metabolites of precursor E.F.A.
105. Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro
106. ETYA, a pleiotropic membraneactive arachidonic acid analogue affects multiple signal transduction pathways in cultured transformed mammalian cells
107. Inhibition of pancreatic carcinoma cell growth by lovastatin
108. Effect of lovastatin alone and as an adjuvant chemotherapeutic agent on hepatoma tissue culture-4 cell growth
109. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation
110. Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol
111. Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21 ras isosprenylation and phenotypic reversion
112. Combination drug study with sodium phenylacetate and gemcitabine against the MiaPaCa human pancreatic cancer xenograft
113. Phase I study of phenylacetate administered twice daily to patients with cancer
114. Inhibitors of prenyl transferases
115. Clinical trials with the farnesyl transferase inhibitor R115777
116. Noncytotoxic approaches to the treatment of advanced pancreatic cancer
117. Advances from genetic clues in pancreatic cancer
118. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas
119. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal antiinflammatory drugs
120. Cyclooxygenase inhibitors exert antiproliferative effects against pancreatic adenocarcioma cell lines that are independent of the level of COX-2 expression
121. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
122. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer
123. Angiogenesis and cancer control: From concept to therapeutic trial
124. Review of three new agents that target angiogenesis matrix metalloproteinases and cyclin-dependent kinases
125. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat
126. A phase 1b study of concurrent administration of marimastat and gemcitibine in non-resectable pancreatic cancer
127. Schedules of 5-FU and the matrix metalloproteinase inhibitor marimistat, a phase I study
128. Marimastat in patients with advanced pancreatic cancer: A dosefinding study
129. Retinoids in pancreatic cancer
130. A phase II pilot trial of 13-cis retinoic acid and interferon-α in patients with advanced pancreatic carcinoma
131. Angiogenesis as a target for tumor treatment
132. Angiogenesis and antiangiogenesis: Perspectives for treatment of solid tumors
133. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness
134. Proteasome inhibitor PS-341 effective as an antiangiogenic agent in the treatment of human pancreatic cancer via the inhibition of NF-kB and subsequent inhibition of vascular growth factor production
135. Constitutive expression of vascular endothelial growth factor correlates with growth and metastases of human pancreatic adenocarcinoma
136. Enhanced expression of urokinase receptor induced through the tissue factor-Factor VIIa pathway in human pancreatic cancer
137. Low serum levels of soluble CD44 variant 6 was significantly associated with poor prognosis in patients with pancreatic cancer
138. Nitrone spin traps and a nitroxide antioxidant inhibit a common pathway of thymocyte apoptosis
139. Induction of type I programmed cell death in U937 cells by the antioxidant butylated hydroxy-toluene or the free radical spin trap, NTBN
140. Adjuvant treatment of murine neuroblastoma with 6-hydroxy dopamine and tempol
141. Ethyrol (amifostine) protects against cumulative cisplatin toxicites
142. An essential role for free radicals and derived species in signal transduction
143. Efficacy of low dose thalidomide in multiple myeloma
144. Thalidomide as a treatment of relapsed and refractory myeloma
145. Thalidomide as an emerging notherapeutic agent
146. Inhibitors of tyrosine kinase
147. Activity of an ABL-specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemia, including CML in blast crisis
148. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits anti-tumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness
149. Studies of the molecular mechanisms in the regulation of telomerase activity
150. Specific association of human telomerase activity with immortal cells and cancer
151. Growth inhibiting effects of telomere mimic-oligonucleotides on human leukemia/lymphoma cells
152. Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states
153. Telomerase activity for the preoperative diagnosis of pancreatic cancer
154. Inhibitory effect of gemcitabine on telomerase in a human pancreatic cancer
155. 9-Nitro-camptothecin therpy of pancreatic cancer
156. Arsenic trioxide-mediated cytotoxicity in prostate and ovarian carcinoma lines
157. The tumor suppressor, PTEN/MMAC-1, dephosphorylates the lipid second messenger, phosphatidyl inositol, 3,4,5-trisphosphate
158. The role of phosphoinositide 3-kinase lipid products in cell function
159. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer
160. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitized the cells to EGF receptor-targeted therapy
161. Differential growth regulation by all trans retinoic acid is determined by protein kinase C in human pancreatic carcinoma cells
162. Identification of genes showing altered expression in antisense K-rastransduced pancreatic cancer cells with suppressed tumorigenicity
163. Intracellular signaling as a parallel distributed process
164. Neural networks
165. Complexity in biological signaling systems
166. Redundant complexity: A critical analysis of intelligent design in biochemistry
167. Recruitment of a hedgehog regulatory circuit in butterfly eyespot evolution
168. Strategies for genetic intervention in pancreatic cancer
169. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer
170. ONYX-015: Clinical data are encouraging
171. Multiple drug resistance: A solvable problem?
172. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo
173. Inhibition of pancreatic tumor cell growth by p23waf1 dominant recombinant adenovirus
174. Cell cycle arrest and inhibition of tumor cell proliferation by p16INK4 mediated by an adenovirus vector
175. Direct gene transfer into rat pancreas using DNA liposomes
176. Bcl-2 proteins: Regulators of apoptosis or mitochondrial homeostasis?
177. BCL-2 antisense therapy in patients with non-Hodgkin's lymphoma
178. Antisense approaches for the treatment of cancer
179. A novel theree-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene and radiotherapy
180. Engineering tissue-specific expression of a recombinant adenovirus-selective transgene transcription in the pancreas using the amylase promotor
181. A phase I clinical trial of lethally irradiated allogenic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma
182. Induction of apoptosis by cancer chemotherapy
183. Mitochondrial control of cell death
184. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity